Skip to content

NGEN

NervGen Pharma Corp.

NASDAQ · Healthcare · Biotechnology · CA

$2.05
−9.69%
Ask drillr
Institutional positioning

13F filings over the trailing two quarters

New 67Increased 20Reduced 7Sold out 3
FilerActionSharesFiled
Empery Asset Management, LPNew Position4,000,000Aug 11, 2026
Rock Springs Capital Management LPNew Position1,208,231Aug 14, 2026
DAFNA Capital Management LLCNew Position1,050,000Aug 14, 2026
Ghisallo Capital Management LLCNew Position1,000,000Aug 14, 2026
ARMISTICE CAPITAL, LLCNew Position678,000Aug 14, 2026
LMR Partners LLPNew Position600,000Aug 14, 2026
MARSHALL WACE, LLPIncreased435,962Aug 13, 2026
UBS Group AGIncreased379,726Aug 13, 2026
Stonepine Capital Management, LLCNew Position271,678Aug 17, 2026
JANE STREET GROUP, LLCNew Position270,750Aug 14, 2026
Woodline Partners LPNew Position250,500Aug 14, 2026
PFG Investments, LLCIncreased217,500Jul 23, 2026
PFG INVESTMENTS, LLCNew Position201,000Apr 27, 2026
BANK OF AMERICA CORP /DE/New Position200,656May 18, 2026
MARSHALL WACE, LLPNew Position200,359May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings